Skip to content
DataLookout
Menu

NCT03768570

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 45 versions: 40 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 50 words Show 4 more changesShow less
    • Primary completion pushed from Oct 31, 2026 to Mar 31, 2027
    • Study completion pushed from Dec 31, 2026 to Jun 30, 2027
    • Secondary endpoints: details revised at 4 of 9 entries
    • Site details revised at 6 of 31 sites
  2. Minor Primary completion pushed from Jun 30, 2026 to Oct 31, 2026v44
  3. Notable Primary completion date: Dec 31, 2025 to Jun 30, 2026
    • Study completion date: Mar 31, 2026 to Dec 31, 2026
    v43
  4. Minor Primary completion date: Jul 31, 2025 to Dec 31, 2025v42
  5. Minor Primary completion date: Mar 31, 2025 to Jul 31, 2025v41
Show 34 earlier versionsHide 34 earlier versions
  1. Notable Start date: Dec 21, 2018 to Oct 25, 2019v39
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 190 to confirmed 82
    • Site details revised at 31 of 31 sites
    v38
  3. Minor Study sites: 30 to 31v37
  4. Minor Site contacts updated at 1 of 30 sitesv36
  5. Minor Study sites: 29 to 30v35
  6. Minor Study sites: 28 to 29v34
  7. Minor Study sites: 27 to 28v33
  8. Minor Site details revised at 1 of 27 sitesv32
  9. Minor Site details revised at 2 of 27 sitesv31
  10. Minor Study sites: 26 to 27v30
  11. Notable Primary completion date: Dec 31, 2023 to Mar 31, 2025
    • Enrollment target: 238 to 190
    • Study completion date: Dec 31, 2024 to Mar 31, 2026
    v28
  12. Minor Study sites: 25 to 26v27
  13. Minor Study sites: 24 to 25v26
  14. Minor Study sites: 23 to 24v25
  15. Minor Study sites: 20 to 23
    • Secondary endpoints: details revised at 1 of 9 entries
    v24
  16. Notable Eligibility criteria expanded, about 7 wordsv23
  17. Minor Study sites: 21 to 20v22
  18. Minor Study sites: 20 to 21v19
  19. Minor Study sites: 16 to 20v18
  20. Minor Site details revised at 2 of 16 sitesv17
  21. Minor Study sites: 14 to 16v16
  22. Minor Site details revised at 1 of 14 sitesv15
  23. Minor Primary completion date: Dec 2023 to Dec 31, 2023
    • Study completion date: Dec 2024 to Dec 31, 2024
    v13
  24. Minor Study sites: 12 to 14v12
  25. Minor Study sites revised (12)v11
  26. Minor Study sites: 7 to 12
    • Secondary endpoints: 8 to 9
    v10
  27. Notable Eligibility criteria expanded, about 24 wordsv9
  28. Minor Study sites: 15 to 7v8
  29. Minor Study sites: 5 to 15v7
  30. Minor Study sites: 3 to 5v6
  31. Minor Site details revised at 1 of 3 sitesv5
  32. Notable Eligibility criteria shortened, about 7 wordsv4
  33. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Feb 2019 to Dec 21, 2018
    v3
  34. Notable Start date: Dec 2018 to Feb 2019v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Disease-free survival
Timeframe: 5 years

Secondary (9)

Non-muscle invasive bladder cancer recurrence rate
Loco-regional control rate between study arms at the 12 week visit
Patterns of disease recurrence between study arms
Compare overall and bladder intact disease-free survival between study arms
Metastasis-free survival between study arms
Show 4 moreShow less
Number and severity of adverse events between study arms
Quality of Life between treatment arms using Functional Assessment of Cancer Therapy-Bladder Cancer (FACT-BL) questionnaire
Cost-effectiveness between study arms
Cost-utility between study arms

Arms and interventions

SurveillanceNo intervention
DurvalumabActive comparator

Drugs: Durvalumab

Sites

31 sites in 3 countries

Canada 15, Spain 8, United Kingdom 8